Article in Disease models & mechanisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors.
Liang ZhengDepartment of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66126, USA.ORCID 0000-0003-0120-9343
Zhijian WuDepartment of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66126, USA.
Noritaka YadaDepartment of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66126, USA.
Szumam LiuDepartment of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66126, USA.
Cindy LinDepartment of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66126, USA.
Antonia BignottiDepartment of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66126, USA.
Xinyang ZhaoDepartment of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66126, USA.
X Long ZhengDepartment of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66126, USA.ORCID 0000-0003-1680-5295
Funding
Transgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ROY A. JENSEN · 2012 to 2026
$40.1M
Using Integrated Omics to Identify Dysfunctional Genetic Mechanisms Influencing Schizophrenia and Sleep DisturbancesP20GM130423 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Diane E Mahoney · 2019 to 2026
$21.5M
Hematology Central Coordinating Center (HCCC) for the NIDDK Hematology Centers ProgramU24DK126127 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Anna E Beaudin, DEREK L STIREWALT · 2020 to 2026
$7.5M
Novel Approaches for the Control of Microbial PathogensP30GM103326 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI LUTKENHAUS, JOSEPH F · 2012 to 2016
$5.3M
Pathogenesis of thrombotic microangiopathiesR01HL164016 · NHLBI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI X. Long Zheng · 2023 to 2026
$2.1M
Mechanism underlying cofactor-dependent proteolysis of von Willebrand FactorR01HL157975 · NHLBI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ZHANG, XIAOHUI FRANK, ZHENG, X. LONG · 2022 to 2025
$1.8M
Spinning-Disk Confocal Microscope for Wide-Field, Super-Resolution, and Live-Cell ImagingS10OD032207 · OD · UNIVERSITY OF KANSAS MEDICAL CENTER · PI SMITH, PETER G · 2022 to 2022
$600k
AABB Foundation NBF 22-09RAmerican Heart Association 23CDA1053102Kansas Institute for Precision Medicine Center of Biomedical Research Excellence COBRE-P20 GM130423National Institute of Genetics 18A2023NCI NIH HHS P30 CA168524NHLBI NIH HHS R01 HL157975NHLBI NIH HHS R01 HL164016NIDDK NIH HHS subcontract under U24DK126127NIDDK NIH HHS U24 DK126127NIDDK NIH HHS U24DK126127NIGMS NIH HHS P20 GM130423NIGMS NIH HHS P30 GM103326NIH HHS R01HL157975-01A1NIH HHS S10 OD032207University of Kansas Medical Center
6 · The paper itself
Abstract
Mutations in the 5'-untranslated region (5'-UTR) of ankyrin repeat domain-containing protein 26 (ANKRD26) are associated with hereditary thrombocytopenia 2 (THC2). However, the causative role of these mutations and the mechanisms underlying THC2 are not fully established. Here, we report, for the first time, that zebrafish carrying a deletion of two nucleotides (Δ2) in the 5'-UTR of ankrd26 recapitulate some of the key laboratory features of THC2. ankrd26ku6 (homozygous for the Δ2 deletion in the 5'-UTR) fish larvae exhibited significantly increased expression of ankrd26 mRNA and protein. Adult ankrd26ku6 fish exhibited spontaneous thrombocytopenia. Furthermore, the thrombocytes from ankrd26ku6 fish showed enhanced ability to adhere and aggregate on a collagen surface under flow. Proteomic profiling demonstrated marked upregulation of Ninjurin 1 in young thrombocytes from ankrd26ku6 fish compared with those from wild-type controls. The ankrd26ku6 fish with a homozygous nacre allele developed myelodysplastic syndrome at old age. ANKRD26 protein levels were also significantly increased in platelets and plasma from patients with immune thrombotic thrombocytopenic purpura compared with those from unaffected controls. We conclude that ANKRD26 overexpression, resulting from either hereditary or acquired mechanisms, contributes to thrombocytopenia, thrombosis and hematologic malignancies.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Modeling ANKRD26 5'-UTR mutation-related thrombocytopenia. · full record | OpenQuestion